# Juventas Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/juventas-therapeutics

- Industry: Pharmaceuticals
- Headquarters: Cleveland, US
- Website: www.juventasinc.com
- Total disclosed funding: $31M
- Latest round: Series B (May 13, 2015)
- Investors on record: 16

## About

Juventas Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies to treat cardiovascular diseases and other health conditions through regenerative medicine and gene therapy.Juventas Therapeutics, Inc. specializes in regenerative medicine, particularly for cardiovascular conditions. The company, headquartered in Cleveland, US, has undergone strategic pivots to enhance its product offerings. CEO Rahul Aras leads the firm, which has attracted interest from investors and raised USD 7.50 mn in its Series B funding round, fully financing its total raised amount of USD 7.50 mn. The most recent investors include Green Cross Corporation and Posco Investment.Juventas Therapeutics develops advanced therapies aimed at repairing damaged heart tissue and improving cardiac function. This includes proprietary regenerative medicine technologies and gene therapy solutions designed to enhance patients' recovery from cardiovascular diseases.Revenue for Juventas Therapeutics primarily stems from its proprietary therapeutic products targeting cardiovascular disease, with ongoing clinical trials and research supporting its monetization strategies. The company utilizes collaborative partnerships and grants to support its financial framework.Juventas Therapeutics aims to expand its product pipeline with new therapies targeting cardiovascular conditions set to launch within the next 18 months. The company is also planning to enter international markets, particularly in Europe and Asia, by 2025. The recent Series B funding will support these initiatives, including product development and market expansion efforts.

## Funding rounds

- Series B, May 13, 2015, $7.5M — Green Cross Corporation, Posco Investment
- Series B, Jul 16, 2012, $22M — Venture Investors, Fletcher Spaght Ventures, Triathlon Medical Partners, Early Stage Partners, Reservoir Venture Partners, Fort Washington Investment Advisors, Glengary, New Science Ventures, Takeda Ventures, Global Cardiovascular Innovation Center
- Series A, Jul 30, 2007, $1.5M — Blue Chip Venture Company, JumpStart, North Coast Ventures, X-Gen

## Investors

- Blue Chip Venture Company (https://capitalatlas.ai/funds/blue-chip-venture-company) — Series A
- JumpStart (https://capitalatlas.ai/funds/jumpstart) — Series A
- North Coast Ventures (https://capitalatlas.ai/funds/north-coast-ventures) — Series A
- X-Gen — Series A
- Venture Investors — Series B
- Fletcher Spaght Ventures (https://capitalatlas.ai/funds/fletcher-spaght-ventures) — Series B
- Triathlon Medical Partners (https://capitalatlas.ai/funds/triathlon-medical-partners) — Series B
- Early Stage Partners (https://capitalatlas.ai/funds/early-stage-partners) — Series B
- Reservoir Venture Partners (https://capitalatlas.ai/funds/reservoir-venture-partners) — Series B
- Fort Washington Investment Advisors — Series B
- Glengary (https://capitalatlas.ai/funds/glengary) — Series B
- New Science Ventures (https://capitalatlas.ai/funds/new-science-ventures) — Series B
- Takeda Ventures (https://capitalatlas.ai/funds/takeda-ventures) — Series B
- Global Cardiovascular Innovation Center — Series B
- Green Cross Corporation — Series B
- Posco Investment (https://capitalatlas.ai/funds/posco-investment) — Series B